Somatostatin receptor type 2 antagonism improves glucagon counterregulation in biobreeding diabetic rats

Diabetes

Volumn 62, Issue 8, 2013, Pages 2968-2977

  Karimian, Negar ^a   Qin, Tairan ^a   Liang, Tao ^a   Osundiji, Mayowa ^a   Huang, Yachi ^a   Teich, Trevor ^b   Riddell, Michael C ^b   Cattral, Mark S ^a,c   Coy, David H ^d   Vranic, Mladen ^a   Gaisano, Herbert Y ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b YORK UNIVERSITY   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CORTICOSTERONE; GLUCAGON; HORMONE RECEPTOR BLOCKING AGENT; NORADRENALIN; PRL 2903; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG; CATECHOLAMINE; CYCLOPEPTIDE; INSULIN; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; SSTR2 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOBREEDING RAT; CATECHOLAMINE RELEASE; CELL INFILTRATION; CELL STRUCTURE; CONTROLLED STUDY; CORTICOSTERONE RELEASE; GLUCAGON RELEASE; GLUCOSE INTOLERANCE; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MALE; NONHUMAN; PANCREAS ISLET ALPHA CELL; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GLUCOSE CLAMP TECHNIQUE; IMPAIRED GLUCOSE TOLERANCE; METABOLISM; PANCREAS; SECRETION (PROCESS); DRUG ANTAGONISM; DRUG EFFECT;

ANIMALS; CATECHOLAMINES; CORTICOSTERONE; DIABETES MELLITUS, TYPE 1; GLUCAGON; GLUCAGON-SECRETING CELLS; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN; MALE; PANCREAS; PEPTIDES, CYCLIC; PREDIABETIC STATE; RATS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 84891692675     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0164     Document Type: Article

References (28)

1. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169-3176
2. Cryer PE. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 2012;153:1039-1048
3. Gaisano HY, Macdonald PE, Vranic M. Glucagon secretion and signaling in the development of diabetes. Front Physiol 2012;3:349
4. Raju B, Cryer PE. Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes: Documentation of the intraislet insulin hypothesis in humans. Diabetes 2005;54:757-764
5. Zhou H, Tran PO, Yang S, et al. Regulation of alpha-cell function by the beta-cell during hypoglycemia in Wistar rats: the "switch-off" hypothesis. Diabetes 2004;53:1482-1487
6. Cheng-Xue R, Gómez-Ruiz A, Antoine N, et al. Tolbutamide controls glucagons release from mouse islets differently than glucose: involvement of KATP channels from both a-cells and d-cells. Diabetes 2013;62:1612-1622
7. Koerker DJ, Ruch W, Chideckel E, et al. Somatostatin: hypothalamic inhibitor of the endocrine pancreas. Science 1974;184:482-484
8. Strowski MZ, Parmar RM, Blake AD, Schaeffer JM. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: An in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 2000;141:111-117
9. Strowski MZ, Blake AD. Function and expression of somatostatin receptors of the endocrine pancreas. Mol Cell Endocrinol 2008;286:169-179
10. Yue JT, Burdett E, Coy DH, Giacca A, Efendic S, Vranic M. Somatostatin receptor type 2 antagonism improves glucagon and corticosterone counterregulatory responses to hypoglycemia in streptozotocin-induced diabetic rats. Diabetes 2012;61:197-207
11. Orci L, Baetens D, Rufener C, et al. Hypertrophy and hyperplasia of somatostatin- containing D-cells in diabetes. Proc Natl Acad Sci USA 1976;73: 1338-1342
12. Singh V, Brendel MD, Zacharias S, et al. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: An in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab 2007;92:673-680
13. Cejvan K, Coy DH, Efendic S. Intra-islet somatostatin regulates glucagons release via type 2 somatostatin receptors in rats. Diabetes 2003;52:1176-1181
14. Hocart SJ, Jain R, Murphy WA, Taylor JE, Coy DH. Highly potent cyclic disulfide antagonists of somatostatin. J Med Chem 1999;42:1863-1871
15. Yue JTY, Riddell MC, Burdett E, Coy DH, Efendic S, Vranic M. Amelioration of hypoglycemia via somatostatin receptor type 2 antagonism in recurrently hypoglycemic diabetic rats. Diabetes 2013;62:2215-2222
16. Bortell R, Yang C. The BB rat as a model of human type 1 diabetes. Methods Mol Biol 2012;933:31-44
17. Marliss EB, Nakhooda AF, Poussier P, Sima AA. The diabetic syndrome of the 'BB' Wistar rat: possible relevance to type 1 (insulin-dependent) diabetes in man. Diabetologia 1982;22:225-232
18. Hanenberg H, Kolb-Bachofen V, Kantwerk-Funke G, Kolb H. Macrophage infiltration precedes and is a prerequisite for lymphocytic insulitis in pancreatic islets of pre-diabetic BB rats. Diabetologia 1989;32:126-134
19. Tang C, Naassan AE, Chamson-Reig A, et al. Susceptibility to fatty acidinducedb-cell dysfunction is enhanced in prediabetic diabetes-prone biobreeding rats: A potential link between b-cell lipotoxicity and islet inflammation. Endocrinology 2013;154:89-101
20. Miles PD, Yamatani K, Brown MR, Lickley HL, Vranic M. Intracerebroventricular administration of somatostatin octapeptide counteracts the hormonal and metabolic responses to stress in normal and diabetic dogs. Metabolism 1994;43:1134-1143
21. Huang YC, Rupnik M, Gaisano HY. Unperturbed islet a-cell function examined in mouse pancreas tissue slices. J Physiol 2011;589:395-408
22. Huang YC, Rupnik MS, Karimian N, et al. In situ electrophysiological examination of pancreatic a cells in the streptozotocin-induced diabetes model, revealing the cellular basis of glucagon hypersecretion. Diabetes 2013;62:519-530
23. Taniyama Y, Suzuki T, Mikami Y, Moriya T, Satomi S, Sasano H. Systemic distribution of somatostatin receptor subtypes in human: An immunohistochemical study. Endocr J 2005;52:605-611
24. Kailey B, van de Bunt M, Cheley S, et al. SSTR2 is the functionally dominant somatostatin receptor in human pancreatic b- and a-cells. Am J Physiol Endocrinol Metab 2012;303:E1107-E1116
25. Ruggere MD, Patel YC. Somatostatin, glucagon, and insulin secretion fromperfused pancreas of BB rats. Am J Physiol 1984;247:E221-E227
26. Patel YC, Wheatley T, Malaisse-Lagae F, Orci L. Elevated portal and peripheral blood concentration of immunoreactive somatostatin in spontaneously diabetic (BBL) Wistar rats: suppression with insulin. Diabetes 1980;29:757-761
27. Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci USA 2006;103:2334-2339
28. Farhy LS, Chan A, Breton MD, Anderson SM, Kovatchev BP, McCall AL. Association of Basal hyperglucagonemia with impaired glucagon counterregulation in type 1 diabetes. Front Physiol 2012;3:40